![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 5 of 5. This is the beginning of the thread.
Posted by Lamdage22 on August 6, 2014, at 6:48:14
?
Posted by Lamdage22 on August 6, 2014, at 7:24:41
In reply to Can Glyx-13 be utilized in schizophrenia?, posted by Lamdage22 on August 6, 2014, at 6:48:14
I found this article:
http://spryliving.com/articles/new-depression-drug-offers-hope/
That Dr says it might be useful for (among others) schizophrenia as well.
He predicts its going to be available in 2015 or 2016
Posted by Lamdage22 on August 8, 2014, at 12:17:01
In reply to Re: Can Glyx-13 be utilized in schizophrenia?, posted by Lamdage22 on August 6, 2014, at 7:24:41
I have contacted Naurex inquiring if they are going to study Schizophrenic patients with Glyx-13 and NRX-1074
Posted by Lamdage22 on September 6, 2014, at 8:28:43
In reply to Re: Can Glyx-13 be utilized in schizophrenia?, posted by Lamdage22 on August 6, 2014, at 7:24:41
I have read somewhere that they are planning to study Glyx-13 for schizophrenia as well, but i can't find it right now.
Posted by Lamdage22 on September 6, 2014, at 8:37:38
In reply to Re: Can Glyx-13 be utilized in schizophrenia?, posted by Lamdage22 on September 6, 2014, at 8:28:43
"About Glycine-Site Functional Partial Agonists
GFPAs modulate the NMDA receptor in a novel and selective way that results in the largest therapeutic index of any known NMDAR modulator. GFPAs are being developed with the goal of achieving the antidepressant efficacy and rapid onset seen with conventional NMDAR modulators, but without their limiting side effects. The efficacy potential of GFPAs has been demonstrated in animal models in a number of CNS diseases, including major depressive disorder, neuropathic pain, schizophrenia, anxiety, Alzheimer's disease and other cognition disorders. In these studies, GFPAs did not exhibit the schizophrenia-like side effects associated with conventional NMDAR modulating drugs. In preclinical studies, Naurex's lead drug candidate, GLYX-13, has demonstrated a wide therapeutic ratio between efficacy and side effects (>/=500:1). Preclinical studies also have shown that the antidepressant effects of GLYX-13 were evident within 20 minutes and lasted at least two weeks after administration of a single dose."
So they have done animal studies! In those, even schizophrenic mice have not reacted with psychosis to Glyx-13/NRX1074
I can't find where a doctor said, that they are planning to study it on Schizophrenic patients.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.